Related references
Note: Only part of the references are listed.Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin
Fernando Cesar Bizerra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis
Sebastian M. Heimann et al.
MYCOSES (2014)
Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization
David R. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
John W. Baddley et al.
BMC INFECTIOUS DISEASES (2013)
Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT
J. El-Cheikh et al.
BONE MARROW TRANSPLANTATION (2013)
Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Micafungin versus Itraconazole for Prophylaxis of Invasive Fungal Infections in Patients undergoing Hematopoietic Stem Cell Transplant
Xiaojun Huang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
Michaela Doering et al.
BMC INFECTIOUS DISEASES (2012)
Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
Michaela Doering et al.
BMC INFECTIOUS DISEASES (2012)
a Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals
C. T. Rieger et al.
MYCOSES (2012)
Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases
Oliver A. Cornely et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Fungal infections in oncology patients: update on epidemiology, prevention, and treatment
Kieren A. Marr
CURRENT OPINION IN ONCOLOGY (2010)
Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies
Yuji Hirata et al.
LEUKEMIA & LYMPHOMA (2010)
Antifungal Activity of Micafungin in Serum
Jun Ishikawa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients
M. Mikulska et al.
BONE MARROW TRANSPLANTATION (2009)
Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry
D. Neofytos et al.
CLINICAL INFECTIOUS DISEASES (2009)
Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update
Dustin T. Wilson et al.
MYCOPATHOLOGIA (2009)
The changing face of epidemiology of invasive fungal disease in Europe
Cornelia Lass-Floerl
MYCOSES (2009)
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw et al.
CLINICAL INFECTIOUS DISEASES (2008)
Population pharmacokinetics of micafungin in adult patients
Tawanda Gumbo et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation
Yasushi Hiramatsu et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation
Satoshi Hashino et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies
Tawanda Gumbo
CURRENT OPINION IN INFECTIOUS DISEASES (2007)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2007)
Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients
M. J. Post et al.
TRANSPLANT INFECTIOUS DISEASE (2007)
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Ernst-Ruediger Kuse et al.
LANCET (2007)
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
Andrew J. Ullmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation
B. Sirohi et al.
BONE MARROW TRANSPLANTATION (2006)
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis
TE Zaoutis et al.
CLINICAL INFECTIOUS DISEASES (2005)
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant
J Hiemenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis
NTE de Wet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients
N de Wet et al.
CLINICAL INFECTIOUS DISEASES (2004)
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
JAH van Burik et al.
CLINICAL INFECTIOUS DISEASES (2004)
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
KA Marr et al.
BLOOD (2002)
Share Paper
